JP2019506889A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019506889A5 JP2019506889A5 JP2018546429A JP2018546429A JP2019506889A5 JP 2019506889 A5 JP2019506889 A5 JP 2019506889A5 JP 2018546429 A JP2018546429 A JP 2018546429A JP 2018546429 A JP2018546429 A JP 2018546429A JP 2019506889 A5 JP2019506889 A5 JP 2019506889A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- cedna
- optionally
- stem
- rolling circle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020004707 nucleic acids Proteins 0.000 claims description 26
- 102000039446 nucleic acids Human genes 0.000 claims description 26
- 150000007523 nucleic acids Chemical class 0.000 claims description 26
- 210000004027 cell Anatomy 0.000 claims description 23
- 101710150114 Protein rep Proteins 0.000 claims 14
- 101710152114 Replication protein Proteins 0.000 claims 14
- 238000005096 rolling process Methods 0.000 claims 14
- 238000000034 method Methods 0.000 claims 12
- 230000010076 replication Effects 0.000 claims 11
- 239000005547 deoxyribonucleotide Substances 0.000 claims 8
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 7
- 238000000338 in vitro Methods 0.000 claims 6
- 230000003612 virological effect Effects 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 5
- 125000003729 nucleotide group Chemical group 0.000 claims 5
- 108020004414 DNA Proteins 0.000 claims 4
- 239000013598 vector Substances 0.000 claims 4
- 108090000565 Capsid Proteins Proteins 0.000 claims 3
- 102100023321 Ceruloplasmin Human genes 0.000 claims 3
- 241000702421 Dependoparvovirus Species 0.000 claims 3
- 238000003776 cleavage reaction Methods 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 230000007017 scission Effects 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 2
- 230000001270 agonistic effect Effects 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 238000006731 degradation reaction Methods 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 230000004962 physiological condition Effects 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 claims 1
- 108091033409 CRISPR Proteins 0.000 claims 1
- 102000053602 DNA Human genes 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- 230000036755 cellular response Effects 0.000 claims 1
- 230000029087 digestion Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 238000010362 genome editing Methods 0.000 claims 1
- 230000008348 humoral response Effects 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 238000003752 polymerase chain reaction Methods 0.000 claims 1
- 108091008146 restriction endonucleases Proteins 0.000 claims 1
- 241000701447 unidentified baculovirus Species 0.000 claims 1
- 241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 description 10
- 208000019423 liver disease Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 3
- 206010069754 Acquired gene mutation Diseases 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 2
- 208000004884 Balkan Nephropathy Diseases 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 208000033626 Renal failure acute Diseases 0.000 description 2
- 201000011040 acute kidney failure Diseases 0.000 description 2
- 208000012998 acute renal failure Diseases 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000001434 glomerular Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 201000010198 papillary carcinoma Diseases 0.000 description 2
- 230000037439 somatic mutation Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 1
- 208000032035 Acute focal bacterial nephritis Diseases 0.000 description 1
- 206010069688 Acute phosphate nephropathy Diseases 0.000 description 1
- 206010072609 Adenine phosphoribosyl transferase deficiency Diseases 0.000 description 1
- 108700037006 Adenine phosphoribosyltransferase deficiency Proteins 0.000 description 1
- 201000011374 Alagille syndrome Diseases 0.000 description 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
- 208000024985 Alport syndrome Diseases 0.000 description 1
- 206010051810 Angiomyolipoma Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 102100030762 Apolipoprotein L1 Human genes 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 208000023635 C1q nephropathy Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000004990 Cardiorenal syndrome Diseases 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- 102100035325 Complement factor H-related protein 5 Human genes 0.000 description 1
- 206010010317 Congenital absence of bile ducts Diseases 0.000 description 1
- 206010060737 Congenital nephrotic syndrome Diseases 0.000 description 1
- 206010011777 Cystinosis Diseases 0.000 description 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000027472 Galactosemias Diseases 0.000 description 1
- 208000009139 Gilbert Disease Diseases 0.000 description 1
- 208000022412 Gilbert syndrome Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 101100323521 Homo sapiens APOL1 gene Proteins 0.000 description 1
- 101000878134 Homo sapiens Complement factor H-related protein 5 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 241000097929 Porphyria Species 0.000 description 1
- 208000010642 Porphyrias Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 206010038540 Renal tubular necrosis Diseases 0.000 description 1
- 201000007981 Reye syndrome Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 208000005838 apparent mineralocorticoid excess syndrome Diseases 0.000 description 1
- 208000005980 beta thalassemia Diseases 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 201000005271 biliary atresia Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 208000007413 cholesterol embolism Diseases 0.000 description 1
- 210000001268 chyle Anatomy 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
- 201000010276 collecting duct carcinoma Diseases 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 201000004954 familial nephrotic syndrome Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 1
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 description 1
- 208000007345 glycogen storage disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 208000003215 hereditary nephritis Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 208000011392 nephropathic cystinosis Diseases 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 201000002464 short-rib thoracic dysplasia 9 with or without polydactyly Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000011296 tyrosinemia Diseases 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021179896A JP7193096B2 (ja) | 2016-03-03 | 2021-11-03 | 非ウイルス的遺伝子導入のための閉鎖型直鎖状二重鎖ｄｎａ |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662303047P | 2016-03-03 | 2016-03-03 | |
| US62/303,047 | 2016-03-03 | ||
| US201662394720P | 2016-09-14 | 2016-09-14 | |
| US62/394,720 | 2016-09-14 | ||
| US201662406913P | 2016-10-11 | 2016-10-11 | |
| US62/406,913 | 2016-10-11 | ||
| PCT/US2017/020828 WO2017152149A1 (en) | 2016-03-03 | 2017-03-03 | Closed-ended linear duplex dna for non-viral gene transfer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021179896A Division JP7193096B2 (ja) | 2016-03-03 | 2021-11-03 | 非ウイルス的遺伝子導入のための閉鎖型直鎖状二重鎖ｄｎａ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019506889A JP2019506889A (ja) | 2019-03-14 |
| JP2019506889A5 true JP2019506889A5 (enExample) | 2020-04-09 |
| JP6994140B2 JP6994140B2 (ja) | 2022-02-03 |
Family
ID=59743259
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018546429A Active JP6994140B2 (ja) | 2016-03-03 | 2017-03-03 | 非ウイルス的遺伝子導入のための閉鎖型直鎖状二重鎖ｄｎａ |
| JP2021179896A Active JP7193096B2 (ja) | 2016-03-03 | 2021-11-03 | 非ウイルス的遺伝子導入のための閉鎖型直鎖状二重鎖ｄｎａ |
| JP2022191114A Pending JP2023024489A (ja) | 2016-03-03 | 2022-11-30 | 非ウイルス的遺伝子導入のための閉鎖型直鎖状二重鎖ｄｎａ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021179896A Active JP7193096B2 (ja) | 2016-03-03 | 2021-11-03 | 非ウイルス的遺伝子導入のための閉鎖型直鎖状二重鎖ｄｎａ |
| JP2022191114A Pending JP2023024489A (ja) | 2016-03-03 | 2022-11-30 | 非ウイルス的遺伝子導入のための閉鎖型直鎖状二重鎖ｄｎａ |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11066679B2 (enExample) |
| EP (2) | EP3423110B1 (enExample) |
| JP (3) | JP6994140B2 (enExample) |
| KR (1) | KR102336362B1 (enExample) |
| CN (2) | CN115287301A (enExample) |
| AU (2) | AU2017228413B2 (enExample) |
| CA (1) | CA3014683A1 (enExample) |
| DK (1) | DK3423110T3 (enExample) |
| ES (1) | ES2898337T3 (enExample) |
| HR (1) | HRP20211697T1 (enExample) |
| IL (2) | IL302398B2 (enExample) |
| LT (1) | LT3423110T (enExample) |
| MX (1) | MX2018010633A (enExample) |
| PT (1) | PT3423110T (enExample) |
| RU (1) | RU2752882C2 (enExample) |
| SG (2) | SG11201806663TA (enExample) |
| WO (1) | WO2017152149A1 (enExample) |
| ZA (1) | ZA201806544B (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107106689A (zh) | 2014-11-05 | 2017-08-29 | 沃雅戈治疗公司 | 用于治疗帕金森病的aadc多核苷酸 |
| KR102584655B1 (ko) | 2014-11-14 | 2023-10-06 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| MX2017006216A (es) | 2014-11-14 | 2018-08-29 | Voyager Therapeutics Inc | Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela). |
| US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
| PT3423110T (pt) | 2016-03-03 | 2021-11-09 | Univ Massachusetts | Adn em dúplex linear de extremidades fechadas para transferência génica não viral |
| RU2758488C2 (ru) | 2016-05-18 | 2021-10-28 | Вояджер Терапьютикс, Инк. | Модулирующие полинуклеотиды |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| JP7374883B2 (ja) | 2017-08-09 | 2023-11-07 | バイオベラティブ セラピューティクス インコーポレイテッド | 核酸分子およびその使用 |
| WO2019051255A1 (en) * | 2017-09-08 | 2019-03-14 | Generation Bio Co. | CLOSED-ENDED DNA (CEDNA) MODIFIED |
| EP3679148A4 (en) * | 2017-09-08 | 2021-06-09 | Generation Bio Co. | LIPID NANOPARTICLE FORMULATIONS FROM NONVIRAL, CAPSID-FREE DNA VECTORS |
| EP3684422B1 (en) | 2017-09-20 | 2023-12-20 | The Regents of the University of California | Connexin-43 gene therapy to restore electrical and cardiac function, and cardiac structure, in arrhythmogenic right ventricular cardiomyopathy |
| US12098385B2 (en) | 2017-09-20 | 2024-09-24 | The Regents Of The University Of California | Gene therapy strategy to restore cardiac electrical and structural function in arrhythmogenic right ventricular cardiomyopathy |
| US11680296B2 (en) * | 2017-10-16 | 2023-06-20 | Massachusetts Institute Of Technology | Mycobacterium tuberculosis host-pathogen interaction |
| US20220290186A1 (en) * | 2017-12-06 | 2022-09-15 | Generation Bio Co. | Gene editing using a modified closed-ended dna (cedna) |
| US20210371877A1 (en) * | 2017-12-18 | 2021-12-02 | Spark Therapeutics, Inc. | Adeno-associated virus (aav) vector lipid nanoparticle compositions and methods of use |
| EP3740571A4 (en) * | 2018-01-19 | 2021-12-08 | Generation Bio Co. | CLOSED-TERM DNA VECTORS OBTAINED FROM CELL-FREE SYNTHESIS AND METHOD FOR OBTAINING CEDNA VECTORS |
| KR20200120649A (ko) * | 2018-02-14 | 2020-10-21 | 제너레이션 바이오 컴퍼니 | 비-바이러스 dna 벡터 및 항체 및 융합 단백질 생산을 위한 이의 용도 |
| BR112020017060A2 (pt) * | 2018-02-22 | 2020-12-15 | Generation Bio Co. | Expressão controlada de transgenes usando vetores de dna de extremidade fechada (cedna) |
| CA3092459A1 (en) * | 2018-03-02 | 2019-09-06 | Generation Bio Co. | Closed-ended dna (cedna) vectors for insertion of transgenes at genomic safe harbors (gsh) in humans and murine genomes |
| CN117757842A (zh) * | 2018-03-15 | 2024-03-26 | 星际治疗有限公司 | 合成dna运载体及使用方法 |
| WO2019191109A1 (en) * | 2018-03-28 | 2019-10-03 | The Board Of Trustees Of The Leland Stanford Junior University | Microrna inhibitors and their use in treating epiretinal membranes |
| MX2020012077A (es) | 2018-05-15 | 2021-03-09 | Voyager Therapeutics Inc | Composiciones y metodos para el tratamiento de la enfermedad de parkinson. |
| EP3796893A1 (en) | 2018-05-23 | 2021-03-31 | Modernatx, Inc. | Delivery of dna |
| WO2019237383A1 (zh) * | 2018-06-16 | 2019-12-19 | 深圳市博奥康生物科技有限公司 | 用于人 tnfsf18 基因编辑的修饰载体、其制备方法及应用 |
| WO2019237391A1 (zh) * | 2018-06-16 | 2019-12-19 | 深圳市博奥康生物科技有限公司 | CRISPR/Cas9 靶向敲除人 TXGP1 基因及其特异性 gRNA |
| WO2019246544A2 (en) * | 2018-06-22 | 2019-12-26 | Asklepios Biopharmaceutical, Inc. | Vectors for gene delivery that persist within cells |
| CN119955796A (zh) | 2018-08-09 | 2025-05-09 | 比奥维拉迪维治疗股份有限公司 | 核酸分子及其用于非病毒基因疗法的用途 |
| WO2020037254A1 (en) * | 2018-08-17 | 2020-02-20 | City Of Hope | Compounds of chemically modified oligonucleotides and methods of use thereof |
| SG11202103151RA (en) | 2018-09-28 | 2021-04-29 | Voyager Therapeutics Inc | Frataxin expression constructs having engineered promoters and methods of use thereof |
| BR112021007102A2 (pt) * | 2018-11-09 | 2021-08-03 | Generation Bio Co. | dna com extremidade fechada modificada (cedna) que compreende repetições terminais invertidas modificadas simétricas |
| AU2020211457A1 (en) * | 2019-01-24 | 2021-09-09 | Generation Bio Co. | Close-ended DNA (ceDNA) and use in methods of reducing gene or nucleic acid therapy related immune response |
| KR20210127935A (ko) * | 2019-02-15 | 2021-10-25 | 제너레이션 바이오 컴퍼니 | 폐쇄형 DNA(ceDNA) 생산에서의 Rep 단백질 활성의 변형 |
| US20220175968A1 (en) * | 2019-03-06 | 2022-06-09 | Generation Bio Co. | Non-active lipid nanoparticles with non-viral, capsid free dna |
| AU2020231228A1 (en) * | 2019-03-06 | 2021-09-02 | Generation Bio Co. | Closed-ended DNA (ceDNA) and immune modulating compounds |
| CA3133330A1 (en) | 2019-03-13 | 2020-09-17 | Generation Bio Co. | Non-viral dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah) therapeutics |
| CA3133255A1 (en) * | 2019-03-13 | 2020-09-17 | Generation Bio Co. | Non-viral dna vectors and uses thereof for expressing fviii therapeutics |
| EP3946470A4 (en) * | 2019-04-05 | 2023-05-31 | Earli Inc. | IMPROVED METHODS AND COMPOSITIONS FOR SYNTHETIC BIOMARKERS |
| JP2022549138A (ja) | 2019-09-18 | 2022-11-24 | インターガラクティック セラピューティクス インコーポレイテッド | 合成ｄｎａベクターおよびその使用法 |
| EP4110931A4 (en) | 2020-02-25 | 2024-03-27 | University of Massachusetts | Inducible single aav system and uses thereof |
| JP7746280B2 (ja) | 2020-03-27 | 2025-09-30 | ジェネレーション バイオ カンパニー | 新規脂質及びそれらのナノ粒子組成物 |
| US20210330759A1 (en) * | 2020-04-22 | 2021-10-28 | The Cleveland Clinic Foundation | Methods and compositions for treating cytokine storm, ards, and acute lung injury using beta-glucocerebrosidase |
| US20230235298A1 (en) | 2020-06-01 | 2023-07-27 | Modernatx, Inc. | Phenylalanine hydroxylase variants and uses thereof |
| WO2022023284A1 (en) | 2020-07-27 | 2022-02-03 | Anjarium Biosciences Ag | Compositions of dna molecules, methods of making therefor, and methods of use thereof |
| CA3189673A1 (en) | 2020-08-23 | 2022-03-03 | Ajay MAGHODIA | Modified baculovirus system for improved production of closed-ended dna (cedna) |
| US20230383311A1 (en) * | 2020-09-16 | 2023-11-30 | Generation Bio Co. | Non-viral dna vectors and uses thereof for expressing fviii therapeutics |
| EP4333886A4 (en) * | 2021-05-07 | 2025-11-12 | Generation Bio Co | NON-VIRAL DNA VECTORS FOR VACCINE ADMINISTRATION |
| US20240261395A1 (en) * | 2021-05-07 | 2024-08-08 | Generation Bio Co. | Lyophilized non-viral dna vector compositions and uses thereof |
| EP4337177A1 (en) | 2021-05-11 | 2024-03-20 | Modernatx, Inc. | Non-viral delivery of dna for prolonged polypeptide expression in vivo |
| AU2022334711A1 (en) | 2021-08-23 | 2024-04-04 | Bioverativ Therapeutics Inc. | Baculovirus expression system |
| CN118139628A (zh) * | 2021-08-23 | 2024-06-04 | 阿维麦克思生物制药公司 | 用于转基因表达的组合物和方法 |
| IL322201A (en) * | 2023-02-17 | 2025-09-01 | Flagship Pioneering Innovations Vii Llc | DNA structures containing modified uracil |
| WO2024197242A1 (en) | 2023-03-23 | 2024-09-26 | Carbon Biosciences, Inc. | Protoparvovirus compositions comprising a protoparvovirus variant vp1 capsid polypeptide and related methods |
| WO2024249438A1 (en) * | 2023-05-26 | 2024-12-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Copiparvovirus genetic vector platform |
| WO2025212926A1 (en) * | 2024-04-05 | 2025-10-09 | University Of Massachusetts | Aav-mediated rhoa knockdown |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| US5252334A (en) | 1989-09-08 | 1993-10-12 | Cygnus Therapeutic Systems | Solid matrix system for transdermal drug delivery |
| US5316908A (en) | 1990-07-13 | 1994-05-31 | Life Technologies, Inc. | Size markers for electrophoretic analysis of DNA |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| AU689815B2 (en) * | 1993-08-30 | 1998-04-09 | Promega Corporation | Nucleic acid purification compositions and methods |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5697899A (en) | 1995-02-07 | 1997-12-16 | Gensia | Feedback controlled drug delivery system |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| US5656016A (en) | 1996-03-18 | 1997-08-12 | Abbott Laboratories | Sonophoretic drug delivery system |
| US5797898A (en) | 1996-07-02 | 1998-08-25 | Massachusetts Institute Of Technology | Microchip drug delivery devices |
| US5783208A (en) | 1996-07-19 | 1998-07-21 | Theratech, Inc. | Transdermal drug delivery matrix for coadministering estradiol and another steroid |
| US7098320B1 (en) | 1996-07-29 | 2006-08-29 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
| US5779708A (en) | 1996-08-15 | 1998-07-14 | Cyberdent, Inc. | Intraosseous drug delivery device and method |
| EP0931158A1 (en) | 1996-09-06 | 1999-07-28 | The Trustees Of The University Of Pennsylvania | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
| US6177403B1 (en) | 1996-10-21 | 2001-01-23 | The Trustees Of The University Of Pennsylvania | Compositions, methods, and apparatus for delivery of a macromolecular assembly to an extravascular tissue of an animal |
| EP1155056A4 (en) | 1998-12-04 | 2004-05-12 | Mosaic Technologies Inc | METHOD OF IMMOBILIZING OLIGONUCLEOTIDES |
| DE10044384A1 (de) * | 2000-09-08 | 2002-04-18 | Medigene Ag | Wirtszellen zur Verpackung von rekombinantem Adeno-assoziiertem Virus (rAAV), Verfahren zu ihrer Herstellung und deren Verwendung |
| US8241622B2 (en) * | 2001-07-13 | 2012-08-14 | University Of Iowa Research Foundation | Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences |
| BRPI0715375A2 (pt) | 2006-08-18 | 2013-06-18 | Hoffmann La Roche | policonjugados para distribuiÇço in vivo de polinucleotÍdeos |
| CA2927045A1 (en) | 2006-10-03 | 2008-04-10 | Muthiah Manoharan | Lipid containing formulations |
| EP3705125B1 (en) | 2007-12-04 | 2023-07-05 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| AU2008340354B2 (en) | 2007-12-04 | 2014-04-17 | Alnylam Pharmaceuticals, Inc. | Folate-iRNA conjugates |
| KR20230098713A (ko) | 2009-06-10 | 2023-07-04 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| US8987377B2 (en) | 2010-11-19 | 2015-03-24 | Alnylam Pharmaceuticals, Inc. | Poly(amide) polymers for the delivery of oligonucleotides |
| EP2500434A1 (en) * | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery |
| PT3423110T (pt) | 2016-03-03 | 2021-11-09 | Univ Massachusetts | Adn em dúplex linear de extremidades fechadas para transferência génica não viral |
-
2017
- 2017-03-03 PT PT177609633T patent/PT3423110T/pt unknown
- 2017-03-03 MX MX2018010633A patent/MX2018010633A/es unknown
- 2017-03-03 EP EP17760963.3A patent/EP3423110B1/en active Active
- 2017-03-03 CN CN202210722790.9A patent/CN115287301A/zh active Pending
- 2017-03-03 IL IL302398A patent/IL302398B2/en unknown
- 2017-03-03 EP EP21183431.2A patent/EP3957331A1/en active Pending
- 2017-03-03 LT LTEPPCT/US2017/020828T patent/LT3423110T/lt unknown
- 2017-03-03 US US16/081,337 patent/US11066679B2/en active Active
- 2017-03-03 CN CN201780014840.5A patent/CN109195636B/zh active Active
- 2017-03-03 CA CA3014683A patent/CA3014683A1/en active Pending
- 2017-03-03 ES ES17760963T patent/ES2898337T3/es active Active
- 2017-03-03 JP JP2018546429A patent/JP6994140B2/ja active Active
- 2017-03-03 WO PCT/US2017/020828 patent/WO2017152149A1/en not_active Ceased
- 2017-03-03 AU AU2017228413A patent/AU2017228413B2/en active Active
- 2017-03-03 DK DK17760963.3T patent/DK3423110T3/da active
- 2017-03-03 IL IL261524A patent/IL261524B2/en unknown
- 2017-03-03 SG SG11201806663TA patent/SG11201806663TA/en unknown
- 2017-03-03 HR HRP20211697TT patent/HRP20211697T1/hr unknown
- 2017-03-03 SG SG10201913688TA patent/SG10201913688TA/en unknown
- 2017-03-03 KR KR1020187028000A patent/KR102336362B1/ko active Active
- 2017-03-03 RU RU2018134295A patent/RU2752882C2/ru active
-
2018
- 2018-10-02 ZA ZA2018/06544A patent/ZA201806544B/en unknown
-
2021
- 2021-06-01 US US17/335,499 patent/US12252703B2/en active Active
- 2021-11-03 JP JP2021179896A patent/JP7193096B2/ja active Active
-
2022
- 2022-11-30 JP JP2022191114A patent/JP2023024489A/ja active Pending
-
2025
- 2025-02-13 US US19/052,351 patent/US20250290094A1/en active Pending
- 2025-04-17 AU AU2025202724A patent/AU2025202724A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019506889A5 (enExample) | ||
| Ahmadi et al. | Viral vectors and extracellular vesicles: innate delivery systems utilized in CRISPR/Cas-mediated cancer therapy | |
| JP7193096B2 (ja) | 非ウイルス的遺伝子導入のための閉鎖型直鎖状二重鎖ｄｎａ | |
| JP7482028B2 (ja) | 血友病ａに対する遺伝子編集用組成物及び方法 | |
| Keeler et al. | Gene therapy 2017: progress and future directions | |
| JP2022009734A (ja) | タイチン系ミオパチー及び他のタイチノパチーの治療のための材料及び方法 | |
| JP2024038327A5 (enExample) | ||
| JP2018506297A5 (enExample) | ||
| TW202043249A (zh) | 編輯rna的方法和組合物 | |
| JP2019530463A (ja) | Ａａｖカプシド設計 | |
| RU2016123086A (ru) | Способы и композиции для лечения болезни хантингтона | |
| JP2020510439A5 (enExample) | ||
| JP7498499B2 (ja) | 心臓、骨格筋、及び筋幹細胞におけるインビボ相同組換え修復 | |
| JP2020532961A5 (enExample) | ||
| JP2022115976A (ja) | ユートロフィン遺伝子を標的とした筋ジストロフィーの治療方法 | |
| JP2020503017A5 (enExample) | ||
| JP2024107295A5 (enExample) | ||
| Dai et al. | Cancer therapy with a CRISPR-assisted telomerase-activating gene expression system | |
| CN105705638A (zh) | 改善的具有高效能的纳米颗粒型寡核苷酸结构及其制备方法 | |
| EP3420093B1 (en) | Micelle based system nuclease encapsulation for in-vivo gene editing | |
| CN115209953A (zh) | 减轻缺血再灌注损伤的合成物和方法 | |
| Fakhiri et al. | Rapid and simple screening of CRISPR guide RNAs (gRNAs) in cultured cells using adeno-associated viral (AAV) vectors | |
| JP2023509178A (ja) | Ｒｎａをターゲティング編集する新しい方法 | |
| EP3953460A1 (en) | Gene-editing systems for modifying a scn9a or scn10a gene and methods of use thereof | |
| WO2025083617A1 (en) | Methods and compositions for nucleic construct delivery |